Zabofloxacin

Zabofloxacin
Names
	Preferred IUPAC name 1-Cyclopropyl-6-fluoro-7-[(8E)-8-(methoxyimino)-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
	Other names DW-224a
Identifiers
CAS Number	219680-11-2 ;
3D model (JSmol)	Interactive image;
ChemSpider	8128482;
PubChem CID	9952872;
UNII	LV66BA6V2G ;
CompTox Dashboard (EPA)	DTXSID10870251 ;
	InChI InChI=1S/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14- Key: ZNPOCLHDJCAZAH-UCQKPKSFSA-N; InChI=1/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14- Key: ZNPOCLHDJCAZAH-UCQKPKSFBL;
	SMILES Fc1c(nc2c(c1)C(=O)C(\C(=O)O)=C/N2C3CC3)N5C\C(=N\OC)C4(CNC4)C5;
Properties
Chemical formula	C19H20FN5O4
Molar mass	401.392
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Zabofloxacin (DW-224a) is an investigational fluoroquinolone antibiotic for multidrug-resistant infections due to Gram-positive bacteria.^[1]^[2]^[3]^[4] It also has activity against Neisseria gonorrhoeae including strains that are resistant to other quinolone antibiotics.^[5]

Zabofloxacin was discovered by Dong Wha Pharmaceuticals and licensed to Pacific Beach BioSciences for development.^[6]

A double-blind, three-arm clinical study of the drug began in March 2010.^[7]

References

^ HyeKyung Han; Sung Eun Kim; Kwang-Hee Shin; Cheolhee Lim; Kyoung Soo Lim; Kyung-Sang Yu; Joo-Youn Cho (October 2013). "Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet". Current Medical Research and Opinion. 29 (10): 1349–1355. doi:10.1185/03007995.2013.825591. PMID 23865727. S2CID 11071210.1349-1355&rft.date=2013-10&rft_id=https://api.semanticscholar.org/CorpusID:11071210#id-name=S2CID&rft_id=info:pmid/23865727&rft_id=info:doi/10.1185/03007995.2013.825591&rft.au=HyeKyung Han&rft.au=Sung Eun Kim&rft.au=Kwang-Hee Shin&rft.au=Cheolhee Lim&rft.au=Kyoung Soo Lim&rft.au=Kyung-Sang Yu&rft.au=Joo-Youn Cho&rfr_id=info:sid/en.wikipedia.org:Zabofloxacin" class="Z3988">
^ Jong-Hwa Lee; Jung-Heun Ha; Dae-Hun Park; Dong-Rack Choi; Gye-Won Lee; Sung-Hoon Ahn & Choong-Yong Kim (2014). "Quantification Of Zabofloxacin In Rat Plasma Using Hplc-Uv Detector And Its Application To A Pharmacokinetic Study". Journal of Liquid Chromatography & Related Technologies. 37 (3): 311–320. doi:10.1080/10826076.2012.745137. S2CID 96104286.311-320&rft.date=2014&rft_id=info:doi/10.1080/10826076.2012.745137&rft_id=https://api.semanticscholar.org/CorpusID:96104286#id-name=S2CID&rft.au=Jong-Hwa Lee&rft.au=Jung-Heun Ha&rft.au=Dae-Hun Park&rft.au=Dong-Rack Choi&rft.au=Gye-Won Lee&rft.au=Sung-Hoon Ahn&rft.au=Choong-Yong Kim&rfr_id=info:sid/en.wikipedia.org:Zabofloxacin" class="Z3988">
^ Kim EJ, Shin WH, Kim KS, Han SS (Nov 2004). "Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent". Drug Chem Toxicol. 27 (4): 295–307. doi:10.1081/DCT-200039708. PMID 15573468. S2CID 13284436.295-307&rft.date=2004-11&rft_id=https://api.semanticscholar.org/CorpusID:13284436#id-name=S2CID&rft_id=info:pmid/15573468&rft_id=info:doi/10.1081/DCT-200039708&rft.aulast=Kim&rft.aufirst=EJ&rft.au=Shin, WH&rft.au=Kim, KS&rft.au=Han, SS&rfr_id=info:sid/en.wikipedia.org:Zabofloxacin" class="Z3988">
^ Park, Hee-Soo; Oh, Sang-Hun; Kim, Hye-Shin; Choi, Dong-Rack; Kwak, Jin-Hwan (2016-11-17). "Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae". Molecules. 21 (11): 1562. doi:10.3390/molecules21111562. ISSN 1420-3049. PMC 6273590. PMID 27869677.
^ Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA (2008). "Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains". Diagn Microbiol Infect Dis. 62 (1): 110–112. doi:10.1016/j.diagmicrobio.2008.05.010. PMID 18620833.110-112&rft.date=2008&rft_id=info:doi/10.1016/j.diagmicrobio.2008.05.010&rft_id=info:pmid/18620833&rft.aulast=Jones&rft.aufirst=RN&rft.au=Biedenbach, DJ&rft.au=Ambrose, PG&rft.au=Wikler, MA&rfr_id=info:sid/en.wikipedia.org:Zabofloxacin" class="Z3988">
^ "Pacific Beach BioSciences and Dong Wha Pharmaceuticals Sign Exclusive License Agreement to Develop and Commercialize Zabofloxacin (PB-101, DW-224a)". GlobeNewswire. August 10, 2007. Archived from the original on March 3, 2016. Retrieved March 27, 2014.
^ IASO Pharma Inc. (2012-05-04). "A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity". Archived from the original on 2022-11-18. Retrieved 2022-11-18.

External links

A Phase 2, Multi-dose, Double-Blind, Randomized, Multicenter, Safety and Efficacy Study of Zabofloxacin vs Moxifloxacin in the Treatment of Mild to Moderate Community-Acquired Pneumonia

[1] HyeKyung Han; Sung Eun Kim; Kwang-Hee Shin; Cheolhee Lim; Kyoung Soo Lim; Kyung-Sang Yu; Joo-Youn Cho (October 2013). "Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet". Current Medical Research and Opinion. 29 (10): 1349–1355. doi:10.1185/03007995.2013.825591. PMID 23865727. S2CID 11071210.1349-1355&rft.date=2013-10&rft_id=https://api.semanticscholar.org/CorpusID:11071210#id-name=S2CID&rft_id=info:pmid/23865727&rft_id=info:doi/10.1185/03007995.2013.825591&rft.au=HyeKyung Han&rft.au=Sung Eun Kim&rft.au=Kwang-Hee Shin&rft.au=Cheolhee Lim&rft.au=Kyoung Soo Lim&rft.au=Kyung-Sang Yu&rft.au=Joo-Youn Cho&rfr_id=info:sid/en.wikipedia.org:Zabofloxacin" class="Z3988">

[2] Jong-Hwa Lee; Jung-Heun Ha; Dae-Hun Park; Dong-Rack Choi; Gye-Won Lee; Sung-Hoon Ahn & Choong-Yong Kim (2014). "Quantification Of Zabofloxacin In Rat Plasma Using Hplc-Uv Detector And Its Application To A Pharmacokinetic Study". Journal of Liquid Chromatography & Related Technologies. 37 (3): 311–320. doi:10.1080/10826076.2012.745137. S2CID 96104286.311-320&rft.date=2014&rft_id=info:doi/10.1080/10826076.2012.745137&rft_id=https://api.semanticscholar.org/CorpusID:96104286#id-name=S2CID&rft.au=Jong-Hwa Lee&rft.au=Jung-Heun Ha&rft.au=Dae-Hun Park&rft.au=Dong-Rack Choi&rft.au=Gye-Won Lee&rft.au=Sung-Hoon Ahn&rft.au=Choong-Yong Kim&rfr_id=info:sid/en.wikipedia.org:Zabofloxacin" class="Z3988">

[3] Kim EJ, Shin WH, Kim KS, Han SS (Nov 2004). "Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent". Drug Chem Toxicol. 27 (4): 295–307. doi:10.1081/DCT-200039708. PMID 15573468. S2CID 13284436.295-307&rft.date=2004-11&rft_id=https://api.semanticscholar.org/CorpusID:13284436#id-name=S2CID&rft_id=info:pmid/15573468&rft_id=info:doi/10.1081/DCT-200039708&rft.aulast=Kim&rft.aufirst=EJ&rft.au=Shin, WH&rft.au=Kim, KS&rft.au=Han, SS&rfr_id=info:sid/en.wikipedia.org:Zabofloxacin" class="Z3988">

[4] Park, Hee-Soo; Oh, Sang-Hun; Kim, Hye-Shin; Choi, Dong-Rack; Kwak, Jin-Hwan (2016-11-17). "Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae". Molecules. 21 (11): 1562. doi:10.3390/molecules21111562. ISSN 1420-3049. PMC 6273590. PMID 27869677.

[5] Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA (2008). "Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains". Diagn Microbiol Infect Dis. 62 (1): 110–112. doi:10.1016/j.diagmicrobio.2008.05.010. PMID 18620833.110-112&rft.date=2008&rft_id=info:doi/10.1016/j.diagmicrobio.2008.05.010&rft_id=info:pmid/18620833&rft.aulast=Jones&rft.aufirst=RN&rft.au=Biedenbach, DJ&rft.au=Ambrose, PG&rft.au=Wikler, MA&rfr_id=info:sid/en.wikipedia.org:Zabofloxacin" class="Z3988">

[6] "Pacific Beach BioSciences and Dong Wha Pharmaceuticals Sign Exclusive License Agreement to Develop and Commercialize Zabofloxacin (PB-101, DW-224a)". GlobeNewswire. August 10, 2007. Archived from the original on March 3, 2016. Retrieved March 27, 2014.

[7] IASO Pharma Inc. (2012-05-04). "A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity". Archived from the original on 2022-11-18. Retrieved 2022-11-18.

[1]

[2]

[3]

[4]

[5]

[6]

[7]